Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion At the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

Next Previous
Search
Trial Profile

A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion At the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; NT 219 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Appendiceal cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Mesothelioma; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Purple Biotech; TyrNovo

    • Most Recent Events

    • 19 Sep 2024 Status changed from active, no longer recruiting to completed.
    • 08 May 2024 Planned End Date changed from 1 Sep 2024 to 1 Jun 2024.
    • 08 May 2024 Planned primary completion date changed from 1 Jun 2024 to 8 May 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top